GLP-1 receptor agonist: Difference between revisions

'''GLP-1 receptor agonists''' (GLP-1 RAs, also called ''incretin mimetics'') are a class of injectable and (in one case) oral peptide medicines that bind and activate the glucagon-like peptide-1 receptor. They were originally developed for [[type 2 diabetes mellitus]] and have since become first-line for [[obesity]], approved for [[cardiovascular risk reduction]] in obesity without diabetes, [[chronic kidney disease]] in T2DM, and [[MASH]] with stage 2–3 fibrosis.

The class has, since 2021, become the single largest growth story in outpatient medicine spending — Ozempic alone accounted for $9.2B in Medicare Part D in 2023, second only to Eliquis across all federal programs.<ref name="cms2023">CMS Medicare Part D Spending Dashboard, 2023 release. Gross spending, not net of rebates.</ref>

The GLP-1 receptor is a class B G-protein-coupled receptor expressed on pancreatic β-cells, hypothalamic satiety neurons, gastric smooth muscle, cardiomyocytes, vascular endothelium, and renal tubules. Activation produces:

* '''β-cell''': glucose-dependent insulin secretion — meaning hypoglycemia risk is low compared to [[sulfonylureas]] or [[insulin]]

* '''α-cell''': glucagon suppression

* '''Stomach''': delayed gastric emptying → improved postprandial glucose, prolonged satiety

* '''CNS''': hypothalamic appetite suppression and modulation of reward circuitry — the mechanism behind both the weight loss and the widely-reported "food noise" quieting

* '''Cardiovascular and renal''': independent of glycemia — endothelial improvement, natriuresis, weight-mediated and weight-independent blood pressure reduction, plaque stabilization

Native GLP-1 is rapidly cleaved by [[DPP-4]] and has a plasma half-life of ~2 minutes. Every clinically useful GLP-1 RA is engineered for DPP-4 resistance, either by amino-acid substitution at position 2 ([[liraglutide]], [[semaglutide]]), structural fusion ([[dulaglutide]]'s Fc domain), or by being a non-mammalian peptide ([[exenatide]], from Gila monster venom).

| [[Exenatide]] || [[Byetta]] (BID), [[Bydureon]] (weekly) || AZ (originally Amylin) || SC || BID or 1×/wk || 2005 || First-in-class. Exendin-4 from ''Heloderma suspectum'' venom. US commercial market discontinued 2024.

| [[Liraglutide]] || [[Victoza]] (T2DM), [[Saxenda]] (obesity) || Novo Nordisk || SC || Daily || 2010 (T2DM), 2014 (obesity) || First daily GLP-1 RA. Acylated for albumin binding.

| [[Albiglutide]] || Tanzeum || GSK || SC || Weekly || 2014 || Withdrawn 2017 (commercial).

| [[Dulaglutide]] || [[Trulicity]] || Eli Lilly || SC || Weekly || 2014 || Fc-fusion construct.

| [[Lixisenatide]] || Adlyxin (US), Lyxumia (EU) || Sanofi || SC || Daily || 2016 || Withdrawn US 2023.

| [[Semaglutide]] || [[Ozempic]] (T2DM SC), [[Wegovy]] (obesity SC), [[Rybelsus]] (oral T2DM) || Novo Nordisk || SC or oral || Weekly SC / Daily PO || 2017 SC, 2019 PO || Highest-revenue medicine on the planet (2024). Wegovy 2.4 mg also approved for CV risk reduction in obesity ([[SELECT trial|SELECT]]) and MASH with fibrosis ([[ESSENCE trial|ESSENCE]]).

| [[Tirzepatide]] || [[Mounjaro]] (T2DM), [[Zepbound]] (obesity) || Eli Lilly || SC || Weekly || 2022 (T2DM), 2023 (obesity) || '''Dual GLP-1 + GIP agonist''' ("twincretin"). Superior weight loss vs semaglutide in [[SURPASS-2 trial|SURPASS-2]] and [[SURMOUNT-1 trial|SURMOUNT-1]].

* '''Type 2 diabetes mellitus''' — first- or second-line per [[ADA Standards of Care|ADA 2025 Standards of Care]], especially when [[ASCVD]], [[heart failure]], [[CKD]], or obesity is co-present

* '''Obesity or overweight with weight-related comorbidity''' — BMI ≥30, or ≥27 with a weight-related condition (semaglutide 2.4 mg, tirzepatide, liraglutide 3 mg)

* '''Cardiovascular risk reduction in obesity without T2DM''' — semaglutide 2.4 mg (SELECT)

* '''MASH with stage 2–3 fibrosis''' — semaglutide (FDA 2025, based on ESSENCE)

* '''CKD in T2DM''' — semaglutide adjunctive label (FLOW)

| '''LEADER''' (2016) || Liraglutide || T2DM + high CV risk || 13% ↓ MACE ''(NEJM 375:311)''

| '''SUSTAIN-6''' (2016) || Semaglutide SC || T2DM + high CV risk || 26% ↓ MACE

| '''REWIND''' (2019) || Dulaglutide || T2DM + CV risk or established CVD || 12% ↓ MACE — first GLP-1 RA benefit shown in ''primary'' prevention

| '''PIONEER-6''' (2019) || Semaglutide PO || T2DM + high CV risk || Non-inferior to placebo (not powered for superiority)

| '''SURPASS-2''' (2021) || Tirzepatide vs semaglutide || T2DM || Tirzepatide superior on HbA1c and weight

| '''STEP-1''' (2021) || Semaglutide 2.4 mg || Obesity without T2DM || ~14.9% body-weight loss at 68 wk

| '''SURMOUNT-1''' (2022) || Tirzepatide || Obesity without T2DM || Up to ~22.5% body-weight loss at 72 wk

| '''SELECT''' (2023) || Semaglutide 2.4 mg || Obesity + established CVD, no T2DM || 20% ↓ MACE — landmark for obesity as a CV target

| '''STEP-HFpEF''' (2023) || Semaglutide || HFpEF + obesity || ↑ functional capacity (KCCQ), ↓ weight

| '''FLOW''' (2024) || Semaglutide || T2DM + CKD || 24% ↓ kidney + CV events; stopped early for efficacy

| '''ESSENCE''' (2025) || Semaglutide 2.4 mg || MASH + fibrosis || Histologic improvement; basis for FDA approval

'''Common (≥10%, often dose-limiting)''':

* Approximately 75% of exenatide users; less with long-acting weekly agents

* '''Pancreatitis''' — labeled warning. Real-world data are mixed; recent large cohorts do not show a clear increase, and some show ''decreased'' acute pancreatitis incidence.

* '''Gallbladder disease''' — cholelithiasis is partly driven by rapid weight loss.

* '''Medullary thyroid carcinoma (MTC) / C-cell hyperplasia''' — boxed warning, based on rodent data (calcitonin rise). Humans show no calcitonin signal. Long-term follow-up >10 years has not been associated with increased thyroid cancer; the Bezin 2023 French case-control study found a weak signal that remains heavily debated. '''Contraindicated in personal or family history of MTC or MEN2.'''

* '''[[NAION]]''' (non-arteritic anterior ischemic optic neuropathy) — emerging signal (Hsu 2025, ''JAMA Ophthalmol''). Small absolute risk increase.

* '''Aspiration risk under anesthesia''' — delayed gastric emptying. ASA 2024 guidance: hold weekly agents 7 days pre-op; daily agents skip the morning dose.

* '''Suicidality''' — initial EMA signal not replicated. Subsequent large studies (including ''JAMA Pediatrics'' 2024) suggest ''reduced'' suicidal ideation. FDA removed suicidality warnings January 2026.

'''Other monitored''':

Native GLP-1 was isolated in the late 1980s by '''Jens Juul Holst''' (Copenhagen) and '''Daniel Drucker''' (Toronto). Its therapeutic potential was obvious — and so was its problem: a 2-minute plasma half-life.

In 1992, '''John Eng''', an endocrinologist at the Bronx VA Medical Center, was reading work by Pisano and Raufman noting that the venom of the [[Gila monster]] (''Heloderma suspectum'') caused [[pancreatitis]] in laboratory animals. Eng hypothesized that the venom must contain something incretin-like — and isolated '''exendin-4''', a 39-amino-acid peptide 53% homologous to human GLP-1, but naturally resistant to DPP-4 cleavage. The VA declined to patent the discovery, so Eng patented it personally in 1993, licensed it to Amylin Pharmaceuticals, and the rest of the class — Byetta in 2005, then Victoza, Trulicity, Ozempic, Mounjaro — flowed from that single venom isolation.

Per [[CMS Drug Spending Dashboards|CMS 2023 spending data]]:

* Diabetes is the single largest Medicare Part D class at $59.4B in 2023

* GLP-1 RAs drove most of the +$13.8B class growth that year

* Ozempic: $9.2B Part D (#2 single medicine across all federal programs)

* Trulicity: $7.4B Part D, $2.9B Medicaid

* Mounjaro: $2.4B Part D (first full year)

These are gross figures — net spend after manufacturer rebates is materially lower, often 30–50% off list.

<references>

<ref name="drucker2022">Drucker DJ (2022). GLP-1 physiology informs the pharmacotherapy of obesity. ''Mol Metab'' 57:101351. doi:10.1016/j.molmet.2021.101351</ref>

</references>